These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 1569449)

  • 1. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
    Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
    J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Smith TL; Cortes J; Giles FJ; Rios MB; Mallard S; Gajewski J; Murgo A; Cheson B; O'Brien S
    J Clin Oncol; 2000 Oct; 18(20):3513-21. PubMed ID: 11032593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
    O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
    Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
    Giles FJ; Kantarjian H; O'Brien S; Rios MB; Cortes J; Beran M; Koller C; Keating M; Talpaz M
    Leuk Lymphoma; 2001 Apr; 41(3-4):309-19. PubMed ID: 11378543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M
    Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.
    Millot F; Brice P; Philippe N; Thyss A; Demeoq F; Wetterwald M; Boccara JF; Vilque JP; Guyotat D; Guilhot J; Guilhot F
    J Pediatr Hematol Oncol; 2002 Jan; 24(1):18-22. PubMed ID: 11902732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
    Kantarjian HM; Talpaz M; Kontoyiannis D; Gutterman J; Keating MJ; Estey EH; O'Brien S; Rios MB; Beran M; Deisseroth A
    J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
    Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
    Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
    Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
    Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; O'Brien S; Beran M; Koller C; Pierce S; Kornblau S; Estey E; Keating MJ; Talpaz M
    Leukemia; 1997 Oct; 11(10):1610-6. PubMed ID: 9324278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
    Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
    Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
    Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
    Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
    Maloisel F; Guerci A; Guyotat D; Ifrah N; Michallet M; Reiffers J; Tertain G; Blanc M; Bauduer F; Brière J; Abgrall JF; Pegourie-Bandelier B; Solary E; Cambier N; Coso D; Vilque JP; Delain M; Harousseau JL; Rousselot P; Belhadj K; Morice P; Attal J; Chabin M; Chastang C; Guilhot J; Guilhot F;
    Leukemia; 2002 Apr; 16(4):573-80. PubMed ID: 11960335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
    Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
    Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; Smith TL; O'Brien S; Pierce S; Kornblau S; Beran M; Keating MJ; Talpaz M
    J Clin Oncol; 1998 Mar; 16(3):882-9. PubMed ID: 9508169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
    Silver RT; Peterson BL; Szatrowski TP; Powell BL; Stock W; Carroll AJ; Bloomfield CD; Schiffer CA; Larson RA
    Leuk Lymphoma; 2003 Jan; 44(1):39-48. PubMed ID: 12691141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.